# ClinicalIntelPulse Sponsor Intel

> ClinicalIntelPulse Sponsor Intel is a paid API for AI agents from clinicalintelpulse.vercel.app, paid per call via x402, $0.2/call, status unknown (last checked 2026-09-15).

Full pipeline analysis for a pharma or biotech company — trial counts by phase, therapeutic-area coverage, FDA history, partnerships, and competitive positioning.

## Facts

- Endpoint: GET https://clinicalintelpulse.vercel.app/api/clinical/sponsor-intel
- Price: $0.2/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-15
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-sponsor-intel-9c6649b2
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_W1xB6UOSQlkS07Mb0PTCp

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-sponsor-intel-9c6649b2
```

Example prompt: Pull the full ClinicalIntelPulse sponsor intel profile for Regeneron — I need their trial count by phase, therapeutic area coverage, FDA history, and competitive positioning for an M&A due diligence review.

## When to prefer this

Use this endpoint when you need a comprehensive, multi-dimensional view of a single pharma or biotech sponsor's pipeline — covering trial phases, therapeutic focus, regulatory track record, and competitive context. Prefer this over disease-specific endpoints when the analysis is company-centric rather than indication-centric, especially for investor due diligence, M&A screening, or partnership evaluation.

## Known failure modes

- Unknown or misspelled company name returns empty or low-confidence results
- Small private biotechs with limited trial registrations may have sparse data
- Payment of 0.2 USDC not fulfilled results in 402 Payment Required error
- Rate limiting or API unavailability returns 5xx error
- Company with recently rebranded name may not resolve correctly

## How this service works

Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-area coverage, FDA approval history, partnerships, competitive positioning and investment catalysts for any sponsor. Worldwide. For investor and M&A agents.

## Output

A structured report covering the sponsor's clinical trial pipeline broken down by phase, the therapeutic areas they are active in, their FDA approval and rejection history, known partnerships or licensing arrangements, and how they are positioned relative to competitors — formatted for investor or M&A decision-making.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "focus": {
       "type": "string"
      },
      "sponsor": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "fda_approvals": [
   {
    "drug": "Patisiran (Onpattro)",
    "type": "NDA",
    "approved": "2018",
    "indication": "hATTR polyneuropathy",
    "first_in_class": true
   },
   {
    "drug": "Givosiran (Givlaari)",
    "type": "NDA",
    "approved": "2019",
    "indication": "Acute hepatic porphyria"
   }
  ],
  "phase3_assets": [
   {
    "drug": "Vutrisiran (Amvuttra)",
    "nctId": "NCT04153149",
    "status": "ACTIVE_NOT_RECRUITING",
    "condition": "ATTR Cardiomyopathy",
    "completion": "2025-Q3",
    "significance": "Key label expansion into ATTR-CM — $3B+ market"
   }
  ],
  "query_summary": {
   "focus": "all",
   "sponsor": "Alnylam Pharmaceuticals"
  },
  "pipeline_summary": {
   "phase1_count": 8,
   "phase2_count": 9,
   "phase3_count": 6,
   "total_active_trials": 23,
   "primary_therapeutic_areas": [
    "Rare genetic diseases (TTR, PH1, AHP)",
    "Cardiovascular (inclisiran)",
    "CNS (Huntington's)"
   ]
  },
  "investment_signals": {
   "risks": [
    "Pricing pressure in rare disease",
    "RNAi delivery competition from Arrowhead"
   ],
   "near_term_catalysts": [
    "HELIOS-B ATTR-CM readout 2025",
    "ALN-APP Phase 2 for early Alzheimer's"
   ],
   "pipeline_value_estimate": "$12-18B risk-adjusted NPV"
  },
  "competitive_position": "Global leader in RNAi therapeutics. 6 approved drugs. Patent portfolio dominant through 2035+.",
  "partnership_activity": "Novartis partnership (inclisiran, cardiovascular) — $9.7B deal. Roche collaborations ongoing. Regeneron RNAi collaboration $400M+."
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-sponsor-intel-9c6649b2/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.vercel.app](https://www.zero.xyz/host/clinicalintelpulse.vercel.app/llms.txt)